Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase II safety study of nivolumab in advanced or metastatic non-small cell lung cancer
2016-003731-37Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Safety of nivolumab. Started May 2022; status: active.
02
Drugs
03
Conditions
Non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-003731-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003731-37.